You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 150 No. 1, January 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Doxycycline Prophylaxis for Shigellosis

ori Ben-Yehuda, MD; Dan Cohen, MSc; Michael Alkan, MD; Aharon Greenbaum, MD; NavaJelin, BSc; Reuben Steinherz, MD

Arch Intern Med. 1990;150(1):209-212.


Abstract

• The efficacy of oral doxycycline, 100 mg/d for 14 days, in reducing the incidence of shigellosis in newcomers to an area hyperendemic for the disease was examined in a double-blind, placebo-controlled trial. Of 107 entrants, 100 completed the study; 50 received the drug and 50 received a placebo. Diarrheal disease and associated symptoms were monitored for 8 weeks. Starting on the 3rd day of the trial, an outbreak was observed, and Shigella flexneri type 2a was isolated from 6 subjects. Eight of the subjects in the treatment group had diarrhea (16%) compared with 37 in the placebo group (74%), providing a 79% protection rate. There was no significant difference in the occurrence of accompanying symptoms between the subjects suffering from diarrhea in both groups, but the duration of disease was shorter in the treatment group. Serologic study of the outbreak showed no significant difference in antibody response to S flexneri between the treatment (14 of 43) and placebo (18 of 39) groups. Doxycycline prophylaxis apparently is effective and probably does not prevent subclinical infection.

(Arch Intern Med. 1990;150:209-212)



Author Affiliations

From the Israel Defence Forces Medical Corps (Drs Ben-Yehuda, Greenbaum, and Steinherz and Mr Cohen); Soroka Medical Center, Beer Sheva, Israel (Dr Alkan); Kupat Holim Center, Tel Aviv, Israel (Ms Jelin); and Department of Pediatrics, Division of Biochemical Genetics, Beilinson Medical Center Petah-Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (Dr Steinherz).


Footnotes

Accepted for publication March 31,1989.

Reprint requests to Section on Human Biochemical Genetics, Department of Pediatrics, Beilinson Medical Center, Petah-Tikva 49100, Israel (Dr Steinherz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.